• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Plasticell announces grant of fundamental CombiCult patents in U.S. and Japan

Plasticell announces grant of fundamental CombiCult patents in U.S. and Japan

February 13, 2012
CenterWatch Staff

Patents for CombiCult, combinatorial cell culture platform technology, have been granted in the U.S. and Japan, according to Plasticell, a biotechnology company specializing in high throughput technologies for directed stem cell differentiation.

CombiCult breaks the bottleneck in stem cell R&D programs—the discovery of optimized stem cell differentiation protocols. CombiCult also allows scientists to develop custom cell culture media (e.g. GMP compatible stem cell expansion media for cell therapy), create high value cell lines for toxicity testing in the pharmaceutical, cosmetic and nutrition industries, and to increase yield and decrease cost of bioprocess manufacturing.

“Plasticell's proprietary technology breaks the major bottleneck in current stem cell research,” commented Sir Martin Evans FRS, a founding member of Plasticell’s scientific advisory board and recipient of the Nobel prize for the isolation of embryonic stem cells. “Having followed CombiCult's development for almost a decade, I am delighted that the importance of this revolutionary technology is now being recognized through multiple industry awards and patents.”

Patents covering CombiCult have now been issued in the U.S., Europe, Japan, Australia and Singapore.

Upcoming Events

  • 06Jun

    Gene & Cell Therapy Regulation: Comparability and Other New Developments

  • 07Jun

    Developing World-Class SOPs: Optimizing Quality and Compliance

  • 08Jun

    Implementing ICH E8 R1 Recommendations Increases Site and Participant Relationship Scoring Measures

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • MAGI East 2023

    MAGI East 2023 Preview: Janssen Reports on Environmental Impact of Trials

  • Complexity-360x240.png

    Phase 3 Trials Significantly Rising in Complexity, Says CSDD

  • Quality Level Scale

    Build Quality into Trials Like You’d Build a House, Says FDA’s BIMO Director

  • DE&I

    Trust-Building, Community Connection Still Essential to DE&I Efforts, Experts Say

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing